This cohort study of 104 462 patients with diabetes in Taiwan found that SGLT2i use vs dipeptidyl peptidase 4 inhibitor (DPP4i) use was associated with reductions of 34% and 44% in the risk of AKI and AKI requiring dialysis. Here, DPP4 is linked to acute kidney injury.